Drug
Lutetium Oxodotreotide Long Acting Octreotide
Lutetium Oxodotreotide Long Acting Octreotide: highest development phase Phase 3, developed by Jiangsu Hengrui Medicine. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Jiangsu Hengrui Medicine
Trials
| Drug | Phase | Indication |
|---|---|---|
| Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide NCT05884255 | Phase 3 | Advanced Gastroenteropancreatic Neuroendocrine Tumor |
Latest
No recent events.
Follow Lutetium Oxodotreotide Long Acting Octreotide on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.